Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,297 | -11,263 | -6,588 | -5,908 | N/A |
| Depreciation Amortization | 799 | 573 | 584 | 619 | N/A |
| Accounts receivable | 153 | -249 | -99 | 89 | N/A |
| Other Working Capital | -1,229 | 3,242 | 39 | 233 | N/A |
| Other Operating Activity | 3,267 | 640 | 277 | 8 | 0 |
| Operating Cash Flow | $-12,308 | $-7,057 | $-5,788 | $-4,960 | $N/A |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -287 | -102 | -60 | 20 | N/A |
| Net Acquisitions | -2,341 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -448 | -337 | -281 | -409 | N/A |
| Other Investing Activity | -448 | -337 | -281 | -409 | 0 |
| Investing Cash Flow | $-3,076 | $-439 | $-340 | $-389 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | -21 | 4 | N/A |
| Common Stock Issued | 15,305 | 1,607 | N/A | 4,121 | N/A |
| Dividend Paid | -614 | -276 | N/A | N/A | N/A |
| Other Financing Activity | 0 | 10,339 | 15,694 | 469 | 0 |
| Financing Cash Flow | $14,691 | $11,669 | $15,674 | $4,594 | $N/A |
| Exchange Rate Effect | -30 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 17,890 | 13,461 | 875 | 1,813 | N/A |
| End Cash Position | 17,167 | 17,890 | 13,461 | 875 | N/A |
| Net Cash Flow | $-723 | $4,429 | $12,585 | $-938 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,308 | -7,057 | -5,788 | -4,960 | N/A |
| Capital Expenditure | -287 | -102 | -60 | 20 | N/A |
| Free Cash Flow | -12,595 | -7,160 | -5,847 | -4,940 | 0 |